Name | Number of supported studies | Average coverage | |
---|---|---|---|
type I pneumocyte | 10 studies | 37% ± 13% | |
type II pneumocyte | 10 studies | 41% ± 15% | |
retinal pigment epithelial cell | 4 studies | 28% ± 4% | |
endothelial cell | 3 studies | 23% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 3 studies | 26% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 1246.55 | 89 / 89 | 94% | 11.54 | 843 / 901 |
skin | 88% | 435.04 | 1598 / 1809 | 64% | 11.46 | 301 / 472 |
lung | 100% | 1888.96 | 576 / 578 | 43% | 3.67 | 501 / 1155 |
pancreas | 100% | 626.16 | 328 / 328 | 40% | 1.65 | 71 / 178 |
adrenal gland | 100% | 2948.21 | 258 / 258 | 32% | 6.07 | 73 / 230 |
breast | 87% | 234.19 | 401 / 459 | 39% | 2.00 | 437 / 1118 |
spleen | 95% | 321.74 | 230 / 241 | 0% | 0 | 0 / 0 |
thymus | 76% | 97.04 | 499 / 653 | 6% | 0.23 | 36 / 605 |
prostate | 76% | 181.39 | 187 / 245 | 4% | 0.26 | 20 / 502 |
brain | 18% | 30.06 | 473 / 2642 | 53% | 7.38 | 373 / 705 |
ovary | 8% | 18.82 | 14 / 180 | 60% | 2.83 | 257 / 430 |
stomach | 44% | 48.71 | 158 / 359 | 10% | 0.59 | 29 / 286 |
bladder | 24% | 25.52 | 5 / 21 | 15% | 0.94 | 75 / 504 |
adipose | 37% | 65.37 | 441 / 1204 | 0% | 0 | 0 / 0 |
liver | 16% | 14.19 | 36 / 226 | 17% | 2.81 | 69 / 406 |
eye | 0% | 0 | 0 / 0 | 26% | 0.90 | 21 / 80 |
intestine | 16% | 16.65 | 159 / 966 | 9% | 0.36 | 46 / 527 |
uterus | 8% | 11.68 | 14 / 170 | 17% | 0.81 | 76 / 459 |
esophagus | 3% | 2.73 | 48 / 1445 | 19% | 0.95 | 34 / 183 |
peripheral blood | 16% | 19.22 | 152 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 9% | 9.03 | 118 / 1335 | 0% | 0 | 0 / 0 |
heart | 8% | 8.91 | 71 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.07 | 1 / 45 |
muscle | 1% | 0.92 | 7 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0009966 | Biological process | regulation of signal transduction |
GO_0060392 | Biological process | negative regulation of SMAD protein signal transduction |
GO_0030512 | Biological process | negative regulation of transforming growth factor beta receptor signaling pathway |
GO_0005886 | Cellular component | plasma membrane |
GO_0005515 | Molecular function | protein binding |
GO_0010314 | Molecular function | phosphatidylinositol-5-phosphate binding |
Gene name | VEPH1 |
Protein name | Ventricular zone expressed PH domain containing 1 Ventricular zone-expressed PH domain-containing protein homolog 1 (Protein melted) |
Synonyms | VEPH KIAA1692 |
Description | FUNCTION: Interacts with TGF-beta receptor type-1 (TGFBR1) and inhibits dissociation of activated SMAD2 from TGFBR1, impeding its nuclear accumulation and resulting in impaired TGF-beta signaling. May also affect FOXO, Hippo and Wnt signaling. . |
Accessions | ENST00000489602.1 F8WBD3 Q14D04 ENST00000487753.5 ENST00000468233.5 [Q14D04-3] C9JRT0 ENST00000494677.5 [Q14D04-3] ENST00000537559.5 [Q14D04-4] C9J4U8 ENST00000479987.5 ENST00000392833.6 [Q14D04-2] ENST00000473907.5 C9IZY4 ENST00000362010.7 [Q14D04-1] ENST00000392832.6 [Q14D04-1] ENST00000461299.5 C9J379 F8WBQ3 ENST00000475050.5 |